Vobramitamab duocarmazine — Investigational Agent
Antibody-Drug Conjugate · Phase 2 · MacroGenics
Mechanism of Action
An antibody-drug conjugate targeting B7-H3 (CD276), delivering a duocarmycin DNA-alkylating payload selectively to B7-H3-overexpressing tumor cells, causing DNA damage and cell death.
Investigational Indications
- Metastatic castration-resistant prostate cancer
- Head and neck squamous cell carcinoma
- Melanoma
- Non-small cell lung cancer